PharmaLogic Expands Radiopharmaceutical Footprint With New Atlanta Facility

PharmaLogic’s new PET radiopharmaceutical facility in Atlanta is designed to boost production capacity and accelerate delivery of critical radioimaging agents.

PharmaLogic has announced the opening of a new positron emission tomography (PET) radiopharmaceutical manufacturing facility in Atlanta, Georgia. The facility marks a significant expansion of the company’s US production network.

The state-of-the-art facility is designed to increase production capacity while supporting research and development of next-generation radiopharmaceuticals.

Radiopharmaceuticals are radioactive compounds used in imaging and targeted therapy that are highly time-sensitive, often requiring rapid production and delivery due to their short half-lives. As demand grows, particularly in oncology and precision medicine, the need for localized manufacturing has become increasingly urgent.

Radiopharmaceuticals play a growing role in areas such as cancer imaging, cardiology and neurology, offering highly targeted approaches that can both detect and treat disease at the molecular level.

PharmaLogic says the Atlanta site is part of a $250 million investment aimed at addressing a shortage of radiopharmaceutical infrastructure in the US.

Located in the Southeast, the new facility is expected to enable faster and more reliable distribution to hospitals and imaging centers, improving patient access to critical diagnostics and treatments across the region.

PharmaLogic is a global CDMO that specializes in diagnostic and therapeutic radiopharmaceuticals, with comprehensive solutions spanning development, manufacturing and distribution of both clinical and commercial-stage radiopharmaceutical products.

Beyond manufacturing, PharmaLogic’s new Atlanta facility will also serve as a hub for innovation. Equipped with advanced PET production technology, it includes dedicated resources for the development of novel radiopharmaceuticals.

In a press release announcing the new facility, Etienne Montagut, President & CEO of PharmaLogic, said, “The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the US. This state-of-the-art PET manufacturing facility will bring advanced radiopharmaceuticals to patients in the Southeast and surrounding areas, and will serve as a hub for supporting the development of next-generation radiopharmaceuticals.”

By expanding its capabilities, PharmaLogic is positioning itself to support both clinical development and commercial-scale production.

The company said the facility represents a significant milestone in PharmaLogic’s commitment to expanding domestic radiopharmaceutical manufacturing infrastructure, advancing patient access to novel diagnostic and therapeutic radiopharmaceuticals across the Southeast and beyond.

The Atlanta opening is the latest in a series of recent facility launches for PharmaLogic, following expansions in cities including Cincinnati, the Bronx, Salt Lake City and Los Angeles.

This growing network reflects the company’s ambition to build a comprehensive radiopharmaceutical manufacturing and distribution platform globally. At present, the company has more than 45 facilities spanning the US, Puerto Rico, Canada and Norway.

Currently, PharmaLogic delivers over 2.5 million doses annually to more than 30 countries across the globe.